Memento Brings Home $93M Series A Souvenir, Picks up Bispecific for Eye Diseases

Why It Matters

The funding and asset acquisition position Memento to challenge existing monotherapies in a $50 billion global eye‑disease market, potentially delivering a best‑in‑class biologic and generating significant upside for investors and partners.

Key Takeaways

• Memento raised $93 million Series A to fund eye‑disease program
• Acquired worldwide rights to bispecific antibody MMT‑205 from MabTics and Curacle
• MMT‑205 targets VEGF and activates Tie2, aiming for best‑in‑class retinal therapy
• Funding led by Forbion, RA Capital, Avego; Sanofi Ventures also participated
• Milestone payments and royalties slated for MabTics, Curacle upon MMT‑205 success

Pulse Analysis

The retinal disease market, driven by age‑related macular degeneration and diabetic macular edema, represents a multi‑billion‑dollar opportunity for innovators. Existing anti‑VEGF injections dominate but require frequent dosing and carry resistance risks. Memento's $93 million Series A infusion not only supplies capital for IND‑enabling studies but also signals investor confidence in a differentiated therapeutic approach that could reshape treatment paradigms.

MMT‑205’s bispecific design merges VEGF inhibition with Tie2 activation, a novel strategy to reinforce vascular stability while suppressing pathological neovascularization. By targeting two complementary pathways, the molecule promises longer durability and potentially fewer injections compared with current monotherapies. Competitors are exploring similar dual‑action concepts, yet Memento’s exclusive rights and early‑stage development give it a timing advantage as the field seeks best‑in‑class solutions.

For the biotech ecosystem, the deal illustrates how strategic licensing and robust financing can accelerate pipeline progression. MabTics and Curacle stand to earn R&D, regulatory and commercial milestones, aligning incentives across the value chain. Should MMT‑205 demonstrate efficacy, it could unlock sizable royalty streams and position Memento for a high‑value partnership or acquisition, reinforcing the attractiveness of eye‑disease platforms to larger pharmaceutical players.